| 
Salvage Therapies
Successful
Salvage Therapy with Darunavir in HIV Patients Who Failed Several Ritonavir-boosted
Protease Inhibitors
- 7/28/06
Benefit
from Adding the Activity of Several Boosted PIs to Improve Response to a Salvage
Therapy in Advanced HIV Disease - 10/05/05
Structured
Treatment Interruption Based on Genotypic Resistance Does Not Benefit Heavily
Pretreated HIV Patients - 9/28/05
Response
of HIV Positive Patients to Long-term Lopinavir/Ritonavir Salvage Therapy
- 8/08/05
Boehringer
Ingelheim Wins FDA Approval to Market Protease Inhibitor Tipranavir (Aptivus)
for Treatment of Drug-resistant HIV
- 6/24/05
Salvage
Therapy Guided by Rules-based or Phenotype-driven HIV Genotypic Drug Resistance
Interpretation with or without Concentration-controlled Intervention - 6/13/05
Drug Concentration
Control Provides No Apparent Help in HIV Salvage Therapy
- 6/08/05
Roche Offers
Fuzeon Free for 60 Days to Patients Enrolled in HIV Drug Expanded Access Programs
- 12/03/04
Treatment
Strategies Analyzed at HIV Meeting in Glasgow, Scotland - 11/17/04
Comparison
of Two Indinavir/Ritonavir Regimens in Patients Failing Their First Protease Inhibitor-based
Regimen - 10/25/04
Salvage
Therapy with Amprenavir, Lopinavir and Ritonavir 400 mg/d Shows Significant Virological
Efficacy -
10/15/04
Lopinavir/Ritonavir
Is an Effective Option for Salvage Therapy in PI-experienced Children
-
10/13/04
Simplification
of Therapeutic Drug Monitoring for Twice-Daily Regimens of Lopinavir/Ritonavir
-
10/04/04
Efficacy,
Safety and Predictive Factors of Virological Success of a Boosted Amprenavir-based
Salvage Regimen -
07/30/04
HIV
Therapy After Treatment Interruption in Patients with Multiple Failure and More
Than 200 CD4+ T Cells
- 07/30/04
Lopinavir/Ritonavir
and Saquinavir Hard Gel Combination Is an Effective Alternative HAART Regimen
-
07/21/04
Double
PI Therapy with Lopinavir/Ritonavir + Saquinavir Is a Potent Option as Salvage
therapy But Is Not Suitable for Patients with Heavy PI Resistance and Very Low
CD4 Count -
07/14/04
Virological
Phenotype Switches in Salvage Therapy with Lopinavir/Ritonavir in Heavily
Pretreated, HIV Vertically-infected Children - 07/14/04
Fosamprenavir
and Lopinavir/Ritonavir BID Are Both Effective Protease Inhibitors for Patients
Failing One or Two Prior PI-based Regimens - 07/12/04
The Triple Protease Inhibitor Regimen Amprenavir
+ Saquinavir + Ritonavir May Be a Viable Salvage Regimen in Heavily PI-experienced
Individuals - 07/02/04
|
|
